Cardiff Oncology (CRDF) director Gary W. Pace buys 30,000 shares in open market

Rhea-AI Filing Summary

Cardiff Oncology director Gary W. Pace bought 30,000 shares of Common Stock in an open-market transaction. The shares were purchased at a price of $1.22 per share. Following this transaction, he directly owns 1,356,376 shares of Cardiff Oncology common stock.

Insider Trade Summary

Net Buyer: 30,000 shares ($36,600)

Net Buy 1 txn

Insider PACE GARY W

Role null

Bought 30,000 shs ($37K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	30,000	$1.22	$37K

Holdings After Transaction: Common Stock — 1,356,376 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 30,000 shares Purchase price: $1.22 per share Shares owned after transaction: 1,356,376 shares +2 more

5 metrics

Shares purchased 30,000 shares Open-market purchase of Common Stock

Purchase price $1.22 per share Price for Common Stock bought on transaction date

Shares owned after transaction 1,356,376 shares Total direct holdings following purchase

Net buy/sell shares 30,000 shares Net effect of reported transactions

Buy transactions count 1 transaction Number of purchase transactions reported

Key Terms

Common Stock, open-market purchase, transaction code P, direct ownership

4 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

transaction code P financial

"transaction_code_description: "Purchase in open market or private transaction""

direct ownership financial

"ownership_type: "direct""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/22/2026 - 09:00 AM Accepted by SEC EDGAR 06/22/2026 - 09:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PACE GARY W

(Last) (First) (Middle)

C/O CARDIFF ONCOLOGY, INC.

11055 FLINTKOTE AVENUE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2026		P		30,000	A	$1.22	1,356,376	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Gary Pace	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cardiff Oncology (CRDF) report for Gary W. Pace?

Cardiff Oncology reported that director Gary W. Pace purchased 30,000 shares of Common Stock. The transaction was an open-market purchase at $1.22 per share, increasing his directly held position in the company.

How many Cardiff Oncology (CRDF) shares does Gary W. Pace hold after this transaction?

After the reported purchase, Gary W. Pace holds 1,356,376 shares of Cardiff Oncology Common Stock. This figure reflects his direct ownership position as disclosed in the Form 4 insider filing.

At what price did Gary W. Pace buy Cardiff Oncology (CRDF) shares?

Gary W. Pace bought 30,000 Cardiff Oncology Common Stock shares at $1.22 per share. The filing describes this as an open-market or private transaction under transaction code P.

What does transaction code P mean in the Cardiff Oncology (CRDF) Form 4?

Transaction code P in the Form 4 indicates a purchase transaction. In this case, it reflects an open-market or private purchase of Cardiff Oncology Common Stock by director Gary W. Pace.

Was the Cardiff Oncology (CRDF) insider transaction a buy or a sell?

The Cardiff Oncology insider transaction was a buy. Director Gary W. Pace executed an open-market purchase of 30,000 Common Stock shares at $1.22 per share, increasing his direct holdings to 1,356,376 shares.